8-K: Health Catalyst Exceeds Expectations in Q2 2024, Projects Strong Growth

Health Catalyst reported strong Q2 2024 financial results, exceeding guidance and demonstrating significant growth in new platform subscription clients.

Summary

• Health Catalyst reported a total revenue of $75.9 million and an adjusted EBITDA of $7.5 million for the second quarter of 2024, both exceeding the mid-point of their guidance.
• The company signed more net new Platform Subscription Clients in the first half of 2024 than in all of 2023.
• They anticipate low-20s net new Platform Subscription Clients for the full year, which would be the strongest year in the company's history for this metric.
• Health Catalyst expects total revenue between $74.5 million and $77.5 million and adjusted EBITDA between $6.0 million and $8.0 million for the third quarter of 2024.
• For the full year 2024, they expect total revenue between $304.0 million and $312.0 million and adjusted EBITDA between $24.0 million and $26.0 million.
• The company has secured a new credit facility of up to $225 million with Silver Point Finance to fuel inorganic growth.
• They announced the acquisitions of Carevive and Lumeon, which are expected to provide additional cross-selling opportunities.
• Health Catalyst anticipates a return to double-digit topline growth and approximately 50% adjusted EBITDA growth in 2025.
• The company expects a dollar-based retention rate of 100% 106% for 2024, excluding an additional 3-4% of revenue growth from non-recurring expansions in 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company exceeding financial guidance, strong growth in new clients, and strategic acquisitions. The securing of a new credit facility and positive future outlook further contribute to the positive sentiment.

Positives

• The company exceeded revenue and adjusted EBITDA guidance for Q2 2024.
• There was significant growth in new platform subscription clients in the first half of 2024.
• The new credit facility provides financial flexibility for future growth.
• The acquisitions of Carevive and Lumeon are expected to create cross-selling opportunities.
• The company is projecting a return to double-digit topline growth and ~50% Adjusted EBITDA growth in 2025.
• The dollar-based retention rate is expected to be strong at 100% 106% for 2024.

Negatives

• The company reported a net loss of $13.5 million for Q2 2024.
• The company has not provided forward-looking guidance for net loss due to the unpredictability of certain items such as stock-based compensation.

Risks

• Changes in laws and regulations could impact the business model.
• Market or industry conditions, regulatory environment, and receptivity to technology and services could change.
• The company could face risks from litigation or security incidents.
• The loss of key clients or partners could negatively affect results.
• The macroeconomic environment, including inflation and interest rates, could impact the business.
• The company's ability to recruit and retain qualified team members could be challenged.

Future Outlook

Health Catalyst anticipates a return to double-digit topline growth and approximately 50% adjusted EBITDA growth in 2025. They have provided revenue and adjusted EBITDA guidance for Q3 2024 and the full year 2024, and updated their bookings expectations for net new Platform Subscription Clients and Dollar-Based Retention Rate.

Management Comments

• Dan Burton, CEO of Health Catalyst, stated he was pleased by the strong financial results, including total revenue of $75.9 million and Adjusted EBITDA of $7.5 million, which exceeded the mid-point of their quarterly guidance.
• The CEO also expressed satisfaction with the company's bookings performance, particularly regarding net new Platform Subscription Clients.
• Management has renewed confidence that they will return to double digit topline growth and achieve ~50% Adjusted EBITDA growth in 2025.

Industry Context

This announcement reflects a positive trend for Health Catalyst in the healthcare analytics sector, demonstrating growth in both revenue and client acquisition. The company's focus on platform subscriptions and strategic acquisitions aligns with the industry's move towards data-driven healthcare solutions. The new credit facility and acquisitions position Health Catalyst to further consolidate its position in the market.

Comparison to Industry Standards

• Health Catalyst's Q2 2024 revenue growth of 4% year-over-year is moderate compared to some high-growth SaaS companies in the healthcare space, but the 114% increase in Adjusted EBITDA is a strong indicator of improved profitability.
• Companies like Veeva Systems and Cerner (now Oracle Health) have shown higher revenue growth rates in the past, but Health Catalyst's focus on data analytics and platform subscriptions differentiates it.
• The company's adjusted EBITDA margin of approximately 10% in Q2 2024 is a positive sign, but still lower than some established software companies with margins exceeding 20%.
• The acquisition strategy is similar to that of other players in the healthcare IT space, such as Oracle's acquisition of Cerner, which aims to expand product offerings and market share.
• The projected growth in net new platform subscription clients is a key metric, and the company's performance in this area is a positive sign for future revenue growth.

Stakeholder Impact

• Shareholders are likely to react positively to the better-than-expected financial results and positive future outlook.
• Employees may be encouraged by the company's growth and financial stability.
• Customers will benefit from the company's expanded product offerings and services.
• Suppliers and creditors may view the company as a more stable and reliable partner due to the new credit facility.

Next Steps

• The company will host a conference call to review the results on August 7, 2024.
• Health Catalyst will continue to focus on growing its platform subscription client base.
• The company will integrate the recently acquired Carevive and Lumeon businesses.
• They will continue to execute on their strategy to return to double-digit topline growth and achieve ~50% Adjusted EBITDA growth in 2025.

Key Dates

Keywords

Health Catalyst, Financial Results, Q2 2024, Adjusted EBITDA, Platform Subscription Clients, Healthcare Analytics, Revenue, Credit Facility, Acquisitions, Data Analytics